Inclusion Criteria:

- Patients with non-Hodgkin's B-cell lymphoma (NHL) including follicular, large cell
and Mantle cell lymphoma will be included.

- Patients in complete clinical remission and determined to have no evidence of active
disease (NED).

- Ambulatory, medically stable persons; community dwelling; able to give informed
consent and available for all study visits; able to understand and comply with
planned study procedures; ECOG performance status less than or equal to 2.

- Medically stable subjects may have underlying illnesses such as hypertension,
diabetes, ischemic heart disease, or hypothyroidism, but their symptoms/signs are
controlled with medical therapy.

- Patients with a non-metastatic secondary solid tumor or malignancies not currently (<
3 months) being treated will be included.

- Patients greater than or equal to 18 years of age who have given informed consent and
signed the IRB approved informed consent.

Exclusion Criteria:

- Patients with Hodgkin's disease, and T-cell lymphoma.

- Patients undergoing antineoplastic therapy.

- Patients who have received chemotherapy within the past 3 months.

- Individuals who were given rituximab (ibritumomab tiuxetan) in < 6 months.

- Patients receiving systemic corticosteroids and/or high-dose inhaled steroids (>800
mcg per day of beclomethasone dipropionate or equivalent).

- Splenectomized individuals will not be included.

- Known allergy to eggs or other components of vaccine (e.g., thimerosal).

- Acute or chronic condition that (in the opinion of the investigator) would render
vaccination unsafe or would interfere with the evaluation of responses (including but
not limited to the following: acute febrile illness, known chronic liver disease;
significant renal disease; oxygen-dependent chronic lung disease, New York Heart
Association Functional Class III or IV dyspnea; unstable or progressive neurologic
disorder; insulin-dependent diabetes mellitus).

- Concomitant use of investigational vaccines and/or other medications within 4 weeks
prior to study entry, or expected use of experimental or licensed vaccines or
blood/blood products prior to study completion.

- Previous exposure to parenteral immunoglobulins or other blood product within 6
months prior to enrollment into the study.

- Subject is enrolled in a conflicting clinical trial.

- Use of experimental vaccines or medications within one month of study entry.

- Any acute or chronic condition which in the opinion of the investigator would render
vaccination unsafe or interfere with the evaluation of response.

- Patients with a known history or risk factors (IV drug abuse or casual sex within the
past year) of Hepatitis B, Hepatitis C, or Human Immunodeficeincy Virus.